← Open Payments lookup

MIKEL ZAMORA: Open Payments

NPI 1518943224 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$3,312 in 176 payments from 15 companies in 2025. Trend: 2023 $2,833 · 2024 $3,123 · 2025 $3,312

Food & beverage: $3,312
CompanyPaymentsAmount
Takeda Pharmaceuticals U.S.A., Inc.22$461
Janssen Biotech, Inc.16$340
QOL Medical, LLC12$328
Celltrion USA Inc.23$325
ABBVIE INC.15$323
Gilead Sciences, Inc.8$252
Madrigal Pharmaceuticals10$227
Aimmune Therapeutics, Inc.16$224
Salix Pharmaceuticals, a division of Bausch Health US, LLC27$213
Ipsen Biopharmaceuticals, Inc7$179

Products named: TREMFYA, Sucraid, VEGZELMA, ENTYVIO, REZDIFFRA, RINVOQ, ZENPEP, IQIRVO.

Industry payments across TX — which companies pay providers there.